EVM
CHRS icon

Eaton Vance Management’s Coherus Oncology CHRS Stock Holding History

Eaton Vance Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-843
Closed -$14K – 1953
2021
Q4 		$14K Buy
843
+150
+22% +$2.62K ﹤0.01% 2472
2021
Q3 		$3K Buy
693
+197
+40% +$2.89K ﹤0.01% 1866
2021
Q2 		$7K Buy
496
+324
+188% +$4.59K ﹤0.01% 2590
2021
Q1 		$3K Buy
+172
New +$2.92K ﹤0.01% 2695

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Eaton Vance Management's CHRS Position: Q1 2022 in Review

Eaton Vance Management sold out of Coherus Oncology (CHRS) in Q1 2022, closing a stake of 843 shares — an estimated $14K sold.

Eaton Vance Management first reported a position in CHRS in Q1 2021 and held it in 4 quarters. The position peaked at $14K in Q4 2021. 183 funds tracked by Wall St. Rank hold CHRS as of Q1 2022.

  • Eaton Vance Management reported no remaining Coherus Oncology position as of Q1 2022 after selling out during the quarter.
  • Eaton Vance Management sold 843 Coherus Oncology shares in Q1 2022, an estimated $14K.
  • Eaton Vance Management first reported a position in Coherus Oncology in Q1 2021 and held it in 4 quarters.
  • Eaton Vance Management's Coherus Oncology position peaked at $14K in Q4 2021.
  • 183 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2022.

Based on Eaton Vance Management's 13F filing for Q1 2022, filed 16 May 2022.